Evidence map›Paper›PMID 41182514›Full record

ArticleJournal of gastrointestinal cancer2025

Predicting Tumor Regrowth in Patients Undergoing Non-Operative Management after Total Neoadjuvant Therapy.

Kamil Erozkan, Emily Simon, Emily Steinhagen, Lauren Henke, Meagan Costedio, Jennifer Eva Selfridge, Satish E Viswanath, Ronald Charles

Abstract read
In one paragraph

Article in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kamil ErozkanDivision of Colorectal Surgery, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Emily SimonDivision of Colorectal Surgery, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Emily SteinhagenDivision of Colorectal Surgery, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Lauren HenkeRadiation Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Meagan CostedioDivision of Colorectal Surgery, Department of Surgery, University Hospitals Ahuja Medical Center, Beachwood, OH, USA.
Jennifer Eva SelfridgeHematology and Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Satish E ViswanathDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
Ronald CharlesDivision of Colorectal Surgery, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. Ronald.Charles@UHHospitals.org.

Funding

Novel radiomic signatures for treatment response to neoadjuvant therapy in rectal cancersR01CA280981 · NCI · EMORY UNIVERSITY · PI ANDREI SARAIVA PURYSKO, Emily Steinhagen · 2024 to 2026
$1.7M
BLRD VA I01 BX006439NCI NIH HHS R01 CA280981
6 · The paper itself

Abstract

introductionTotal neoadjuvant treatment (TNT) has become the standard of care for locally advanced rectal cancer (LARC), leading to increased rates of complete clinical response and expanding the potential for organ preservation through non-operative management (NOM) protocols. Despite these advances, tumor regrowth remains a concern, necessitating vigilant surveillance to ensure early detection. However, adherence to surveillance protocols is often suboptimal, and the factors influencing tumor regrowth during NOM have not been well defined. This study aims to identify predictors of tumor regrowth in patients undergoing NOM after TNT.

methodWe conducted a retrospective review of patients with LARC who completed TNT at a single institution between 2019 and 2024. Patients who achieved sustained complete clinical response (cCR) for at least 12 months, as well as those who experienced tumor regrowth following cCR, were included. Patients with suspected regrowth who subsequently underwent surgery and were found to have a pathologic complete response (pCR) were excluded. Univariate analyses were performed to compare demographic, histopathologic, biochemical, clinical, radiological, and treatment-related factors between patients who experienced tumor regrowth and those who did not. The primary objective of our study was to identify predictors of tumor regrowth.

resultsAmong 137 patients with LARC, 44 patients (32.1%) achieved cCR following completion of TNT. Of these, 10 patients experienced tumor regrowth and subsequently underwent surgery, with histopathology revealing a pCR in 2 cases. Currently, 11 patients remain in their first year of NOM, and 3 patients were lost to follow-up. In total, 20 patients sustained cCR. A total of 28 patients (25% female) with a mean age of 62.4 years (± 13) were included in the univariate analysis. No statistically significant differences were observed in demographic, histopathologic, biochemical, clinical, radiological, or treatment-related factors between patients who experienced tumor regrowth and those who did not (Table 1).

conclusionThis study did not identify any predictors of tumor regrowth in patients undergoing NOM after TNT. The limited number of events severely restricted the power to detect statistically meaningful associations. Nevertheless, this area warrants further investigation to better tailor surveillance strategies and optimize NOM recommendations.

Indexed as

Neoadjuvant TherapyNeoplasm Recurrence, LocalRectal NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesClinical complete responseNon-operative managementRectal CancerTotal mesorectal excisionTotal Neoadjuvant TherapyTumor regrowth

Identifiers

PMID41182514
PMCPMC12583335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.